Publicaciones
-
Hidalgo, I; Sorolla, MA; Sorolla, A; Salud, A; Parisi, E
Secreted Phospholipases A2: Drivers of Inflammation and Cancer
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 25 -. .
-
Rodríguez, JV; Prieto, A; Vilaprinyo, E; Bonet, M; Diez, M; Salud, A; Montal, R
Surrogate endpoints in phase III randomized trials of advanced gastroesophageal cancer: A systematic review and meta-analysis (vol 201, 104416, 2024)
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 202 104466-104466. .
-
Rodríguez, JV; Prieto, A; Vilaprinyo, E; Bonet, M; Diez, M; Salud, A; Montal, R
Surrogate endpoints in phase III randomized trials of advanced gastroesophageal cancer: A systematic review and meta-analysis
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 201 104416-104416. .
-
Valladares-Ayerbes, M; Safont, MJ; Flores, EG; García-Alfonso, P; Aranda, E; Muñoz, AML; Ferrer, EF; Nogueras, LC; Rodríguez-Salas, N; Aparicio, J; Muñoz, ML; Cáceres, PPP; Trujillo, OAC; Tocino, RV; Fernández, MS; Salud-Salvia, A; Sureda, BM; Garcia-Carbonero, R; Conesa, MAV; Vila, AL
Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study
CLINICAL & TRANSLATIONAL ONCOLOGY -. .
-
Marqués M; Pont M; Hidalgo I; Sorolla MA; Parisi E; Salud A; Sorolla A; Porcel JM
MicroRNAs Present in Malignant Pleural Fluid Increase the Migration of Normal Mesothelial Cells In Vitro and May Help Discriminate between Benign and Malignant Effusions.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 24 -. .
-
Pont, M; Marques, M; Sorolla, MA; Parisi, E; Urdanibia, I; Morales, S; Salud, A; Sorolla, A
Applications of CRISPR Technology to Breast Cancer and Triple Negative Breast Cancer Research
Cancers 15 -. .
-
Parisi, E; Hidalgo, I; Montal, R; Pallise, O; Tarragona, J; Sorolla, A; Novell, A; Campbell, K; Sorolla, MA; Casali, A; Salud, A
PLA2G12A as a Novel Biomarker for Colorectal Cancer with Prognostic Relevance
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 24 -. .
-
Oronich, A; Pallise, O; Salud, A; Montal, R
Genomic alterations and targeted therapies in extrahepatic cholangiocarcinoma
Hepatoma Research 9 -. .
-
Valladares-Ayerbes M; Garcia-Alfonso P; Muñoz Luengo J; Pimentel Caceres PP; Castillo Trujillo OA; Vidal-Tocino R; Llanos M; Llorente Ayala B; Limon Miron ML; Salud A; Cirera Nogueras L; Garcia-Carbonero R; Safont MJ; Falco Ferrer E; Aparicio J; Vicente Conesa MA; Guillén-Ponce C; Garcia-Teijido P; Medina Magan MB; Busquier I; Salgado M; Lloansí Vila A
Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study.
Cancers 14 -. .
-
Porcel, JM; Sorolla, A; Parisi, E; Bielsa, S; Salud, A; Sorolla, MA
Cell-free DNA Concentration and Pattern Fragmentation in Pleural Fluid and Plasma to Detect Malignant Effusions.
Annals of the American Thoracic Society 19 854-856. .
-
Benavides, M; Gómez-España, A; García-Alfonso, P; González, CG; Viéitez, JM; Rivera, F; Safont, MJ; Abad, A; Sastre, J; Valladares-Ayerbes, M; Carrato, A; González-Flores, E; Robles, L; Salud, A; Alonso-Orduña, V; Montagut, C; Asensio, E; Díaz-Rubio, E; Aranda, E
Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
EJSO 48 1123-1132. .
-
Elez, Elena; Gómez-España MA; Gravalos, Cristina; Garcia-Alfonso, Pilar; Ortiz-Morales MJ; Losa, Ferran; Díaz IA; Graña B; Toledano-Fonseca, Marta; Valladares-Ayerbes, Manuel; Polo, Eduardo; Salgado, Mercedes; Martinez de Castro, Eva; Safont MJ; Salud, Antonieta; Ruiz-Casado, Ana; Tabernero, Josep; Riesco MDC; Rodriguez-Ariza, Antonio; Aranda, Enrique
Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial.
BRITISH JOURNAL OF CANCER 126 874-880. .
Proyectos
- Ajuts per a la contractació de personal investigador novell (FI)
- Predicción de micrometástasis en pacientes con cáncer de colon localizado de alto riesgo
- Dimerizaciones de HER2 como elemento de decición en la terapia dirigida anti-HER2 frente al cáncer de mama
- UTILITAT PRONOSTICA DELS PERFILS D'EXPRESSIO PROTEICA EN PACIENTS AMB TUMOR RESIDUAL VIABLE (>1.0 CM) DESPRES DE LA QUIMIOTERAPIA NEOADJUVANT EN CANCER DE MAMA
- Cáncer de mama: utilidad pronóstica de los Perfiles de Expresión Proteica en pacientes con tumor residual viable (>1.0 cm) tras quimioterapia neoadyuvante
